Digestive diseases (Basel, Switzerland) · 2026
Analysis of <italic>Helicobacter pylori</italic> Resistance and Its Trends in Chongqing: A 10-Year Retrospective Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Na-Yun Su, Yu-Xiang Liu, Qing Shi, Xin-Yi Huang, He Ma, Hao-Feng Li, Tao Fu, Yan Zheng, Shengren Lu, Xiao-Chun Shen, Chun-Hui Lan
Аннотация
INTRODUCTION: The high rates of Helicobacter pylori resistance to antibiotics and increasing eradication failure have received much attention worldwide.
METHODS: Gastric mucosa specimens were collected from 7,921 patients with H. pylori infection confirmed by urea breath test from January 2015 to December 2024. H. pylori isolation and culture were performed, followed by antimicrobial susceptibility testing.
RESULTS: The overall and multidrug resistance (MDR) rates of the 5,205 H. pylori isolates to antibiotics were 95.93% and 18.83%, respectively. The listed antibiotic resistance rates in descending order were metronidazole (94.33%), levofloxacin (36.14%), clarithromycin (32.10%), amoxicillin (0.48%), and furazolidone or tetracycline (0%). The analysis demonstrated no significant difference between resistance rates for periods 2015-2019 (95.90%) and 2020-2024 (96.11%) (p > 0.05). Resistance rates differed significantly between the two periods: levofloxacin (35.33% vs. 41.62%), clarithromycin (27.86% vs. 60.93%), and amoxicillin (0.33% vs. 1.50%) (p < 0.05). The MDR rates increased significantly from 16.75% in 2015-2019 to 32.93% in 2020-2024 (p < 0.001). Treatment-experienced patients demonstrated elevated resistance levels and MDR rates (99.31% and 39.45%) in comparison to treatment-naïve individuals (94.99% and 15.02%; p ≤ 0.001). Besides, treatment-experienced patients exhibited significantly higher resistance rates to metronidazole (97.92%), clarithromycin (67.47%), levofloxacin (46.02%), and amoxicillin (1.04%) compared to treatment-naïve patients (92.54%, 32.07%, 35.04%, 0%; p < 0.001).
CONCLUSION: The study revealed elevated overall resistance rates and MDR rates of H. pylori to metronidazole, clarithromycin, and levofloxacin, with significantly higher rates observed in treatment-experienced patients. Notably, a rising pattern in resistance rates to levofloxacin, clarithromycin, amoxicillin, and MDR rates was observed in recent years.
METHODS: Gastric mucosa specimens were collected from 7,921 patients with H. pylori infection confirmed by urea breath test from January 2015 to December 2024. H. pylori isolation and culture were performed, followed by antimicrobial susceptibility testing.
RESULTS: The overall and multidrug resistance (MDR) rates of the 5,205 H. pylori isolates to antibiotics were 95.93% and 18.83%, respectively. The listed antibiotic resistance rates in descending order were metronidazole (94.33%), levofloxacin (36.14%), clarithromycin (32.10%), amoxicillin (0.48%), and furazolidone or tetracycline (0%). The analysis demonstrated no significant difference between resistance rates for periods 2015-2019 (95.90%) and 2020-2024 (96.11%) (p > 0.05). Resistance rates differed significantly between the two periods: levofloxacin (35.33% vs. 41.62%), clarithromycin (27.86% vs. 60.93%), and amoxicillin (0.33% vs. 1.50%) (p < 0.05). The MDR rates increased significantly from 16.75% in 2015-2019 to 32.93% in 2020-2024 (p < 0.001). Treatment-experienced patients demonstrated elevated resistance levels and MDR rates (99.31% and 39.45%) in comparison to treatment-naïve individuals (94.99% and 15.02%; p ≤ 0.001). Besides, treatment-experienced patients exhibited significantly higher resistance rates to metronidazole (97.92%), clarithromycin (67.47%), levofloxacin (46.02%), and amoxicillin (1.04%) compared to treatment-naïve patients (92.54%, 32.07%, 35.04%, 0%; p < 0.001).
CONCLUSION: The study revealed elevated overall resistance rates and MDR rates of H. pylori to metronidazole, clarithromycin, and levofloxacin, with significantly higher rates observed in treatment-experienced patients. Notably, a rising pattern in resistance rates to levofloxacin, clarithromycin, amoxicillin, and MDR rates was observed in recent years.